Pfizer expands diabetes portfolio with Sciwind deal. Pfizer has licensed Sciwind Biosciences' type 2 diabetes drug ecnoglutide, with potential milestone payments reaching $495 million. The agreement marks Pfizer's strategic push into China's metabolic disease market, following a similar GLP-1 drug licensing deal in December. Ecnoglutide, approved in China in January, belongs to the rapidly growing GLP-1 receptor agonist class competing against treatments from Novo Nordisk, Eli Lilly, and others. The drug will target mainland China's commercial market, though it notably will not be covered by China's state health insurance scheme unlike competing therapies. This deal reflects intensifying competition in the lucrative diabetes and weight management sector as pharmaceutical companies race to capitalize on growing demand for metabolic treatments globally.
Post from MarketNews_en
Log in to interact with content.